icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
Daclatasvir+SOF at EASL 2016
 
 
  All-Oral Treatment with Daclatasvir Plus Sofosbuvir Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: An Analysis of ALLY-3 and ALLY-3+ - (04/20/16)
 
Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis - (04/20/16)
 
Daclatasvir Plus Sofosbuvir With or Without Ribavirin for Treatment of Chronic HCV Infection in Patients With Advanced Liver Disease: Results of a European Compassionate Use Programme - (04/20/16)
 
High Sustained Virologic Response Rates in Patients Infected With HCV genotype 2 With Baseline NS5A Polymorphisms Treated With Daclatasvir-Based Regimens - (04/20/16)
 
Sustained Virologic Response to Daclatasvir and Sofosbuvir, With or Without Ribavirin, Among Patients in the French Daclatasvir ATU programme Infected With HCV Genotypes 4, 5 and 6 - (05/02/16)
 
Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Infection in Patients With Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Programme - (04/20/16)
 
Effectiveness of Daclatasvir-Based Therapy in Patients With Chronic Hepatitis C in Europe: Experience From the Named Patient Program - (05/02/16)
 
Factors Impacting SVR12 for Patients With Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir With Ribavirin in the ALLY-1 Study - (05/02/16)
 
Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentre Treatment Protocol - (04/21/16)
 
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate Use Programme - (04/20/16)
 
Next-Generation Sequencing Analysis of NS5A and NS5B Minor Resistance-Associated Variants in Patients with HCV Genotype 3 Infection who Failed Treatment with Daclatasvir Plus Sofosbuvir - (04/20/16)
 
The International Liver Congress™
EASL - European Association for the
Study of the Liver

Barcelona, Spain
13-17 April 2016